Compare McKesson Corporation (MCK) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Marqeta Inc — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Marqeta Inc trades at $18.11 (market cap $1.82B). The key difference: McKesson Corporation is far larger — about 59.6× Marqeta Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Marqeta Inc for 44 Days on average.
| MCK | MQ | |
|---|---|---|
Market Cap | $108.46B | $1.82B |
Volume | 712,607 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $995.69 | $20.32 |
52-Week Low | $725.17 | $15.04 |
Typical Hold Time | 74 Days | 44 Days |
Enterprise Value | $115.00B | $1.13B |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Marqeta (MQ) trades at $17.44, up 2.23% today, showing strong momentum after beating earnings expectations for three consecutive quarters. The stock displays a bullish technical outlook with positive moving average signals, though valuation metrics remain elevated with a P/E of 193.83. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight ongoing business expansion despite mixed analyst sentiment.
MQ presents a high-risk, high-reward opportunity with improving fundamentals but premium valuation. Revenue growth has recovered from 2024 lows, and cash flow turned positive in 2025. However, the stock trades above most analyst targets, and contract renewals in Q3 2026 create near-term uncertainty. Investors should weigh growth potential against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
